Fitness of Escherichia coli mutants with reduced susceptibility to tigecycline

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 5, 2016, Pages 1307-1313

  Linkevicius, Marius ^a   Anderssen, Jytte Mark ^b   Sandegren, Linus ^a   Andersson, Dan I ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BILE SALT; LIPOPOLYSACCHARIDE; TIGECYCLINE; ANTIINFECTIVE AGENT; CARRIER PROTEIN; MINOCYCLINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIUM MUTANT; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SENSITIVITY; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PERITONITIS; PH; THIGH INFECTION; UPREGULATION; ACTIVE TRANSPORT; ANALOGS AND DERIVATIVES; ANIMAL; ANTIBIOTIC RESISTANCE; BIOSYNTHESIS; DRUG EFFECTS; ESCHERICHIA COLI INFECTION; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; OUTBRED STRAIN; PATHOLOGY; PHYSIOLOGICAL STRESS; PHYSIOLOGY;

ANIMALS; ANIMALS, OUTBRED STRAINS; ANTI-BACTERIAL AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; MEMBRANE TRANSPORT PROTEINS; MICE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MINOCYCLINE; STRESS, PHYSIOLOGICAL;

EID: 84965036364     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv486     Document Type: Article

References (23)

1. WHO. Antimicrobial Resistance: Global Report on Surveillance 2014. 2014: 1-256. http://www.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1.
2. Petersen PJ, Jacobus NV,WeissWJ et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43: 738-44.
3. Sum PE, Petersen P. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg Med Chem Lett 1999; 9: 1459-62.
4. Sun Y, Cai Y, Liu X et al. The emergence of clinical resistance to tigecycline. Int J Antimicrob Agents 2013; 41: 110-6.
5. Linkevicius M, Sandegren L, Andersson DI. Mechanisms and fitness costs of tigecycline resistance in Escherichia coli. J Antimicrob Chemother 2013; 68: 2809-19.
6. Datsenko KA, Wanner BL. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci USA 2000; 97: 6640-5.
7. Yu D, Ellis HM, Lee EC et al. An efficient recombination system for chromosome engineering in Escherichia coli. Proc Natl Acad Sci USA 2000; 97: 5978-83.
8. Gullberg E, Cao S, Berg OG et al. Selection of resistant bacteria at very low antibiotic concentrations. PLoS Pathog 2011; 7: e1002158.
9. Heuveling J, Possling A, Hengge R. A role for Lon protease in the control of the acid resistance genes of Escherichia coli. Mol Microbiol 2008; 69: 534-47.
10. Begley M, Gahan CGM, Hill C. The interaction between bacteria and bile. FEMS Microbiol Rev 2005; 29: 625-51.
11. Picken RN, Beacham IR. Bacteriophage-resistant mutants of Escherichia coli K12. Location of receptors within the lipopolysaccharide. J Gen Microbiol 1977; 102: 305-18.
12. Thanassi DG, Cheng LW, Nikaido H. Active efflux of bile salts by Escherichia coli. J Bacteriol 1997; 179: 2512-8.
13. Rosenberg EY, Bertenthal D, Nilles ML et al. Bile salts and fatty acids induce the expression of Escherichia coli AcrAB multidrug efflux pump through their interaction with Rob regulatory protein. Mol Microbiol 2003; 48: 1609-19.
14. Griffith KL, Shah IM,Wolf RE. Proteolytic degradation of Escherichia coli transcription activators SoxS and MarA as the mechanismfor reversing the induction of the superoxide (SoxRS) and multiple antibiotic resistance (Mar) regulons. Mol Microbiol 2004; 51: 1801-16.
15. Rowley D. Sensitivity of rough gram-negative bacteria to the bactericidal action of serum. J Bacteriol 1968; 95: 1647-50.
16. Opal S, Cross A, Gemski P. K antigen and serum sensitivity of rough Escherichia coli. Infect Immun 1982; 37: 956-60.
17. Cross AS, Kim KS, Wright DC et al. Role of lipopolysaccharide and capsule in the serum resistance of bacteremic strains of Escherichia coli. J Infect Dis 1986; 154: 497-503.
18. Burns SM, Hull SI. Comparison of loss of serum resistance by defined lipopolysaccharide mutants and an acapsular mutant of uropathogenic Escherichia coli O75:K5. Infect Immun 1998; 66: 4244-53.
19. Phan M-D, Peters KM, Sarkar S et al. The serum resistome of a globally disseminated multidrug resistant uropathogenic Escherichia coli clone. PLoS Genet 2013; 9: e1003834.
20. Torres-Cabassa AS, Gottesman S. Capsule synthesis in Escherichia coli K-12 is regulated by proteolysis. J Bacteriol 1987; 169: 981-9.
21. Markovitz A. Regulatory mechanisms for synthesis of capsular polysaccharide in mucoid mutants of Escherichia coli K12. Proc Natl Acad Sci USA 1964; 51: 239-46.
22. Parker CT, Kloser AW, Schnaitman CA et al. Role of the rfaG and rfaP genes in determining the lipopolysaccharide core structure and cell surface properties of Escherichia coli K-12. J Bacteriol 1992; 174: 2525-38.
23. Keeney D, Ruzin A, McAleese F et al. MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli. J Antimicrob Chemother 2008; 61: 46-53.